05.03.2024 19:00:06 - dpa-AFX: GNW-Adhoc: Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program Tenth tranche fully issued and paid-up
Oxurion Receives EUR 300,000 in the framework of the Atlas Funding Program
Tenth tranche fully issued and paid-up
Leuven, BELGIUM, 05 March - 07.00 PM CET - Oxurion NV (Euronext Brussels: OXUR),
a biopharmaceutical company based in Leuven, today communicates it has received
an aggregate amount of EUR 300,000 in the framework of the Atlas Funding
Program.
On March 4, 2024, the Company issued the Tenth Tranche consisting of 12
convertible bonds, for an aggregate amount of EUR 300,000.
This tranche has been issued in accordance with the agreement reached with Atlas
end of 2023, as further described in the press release issued by the Company on
December 28, 2023.
About Oxurion
Oxurion (Euronext Brussels: OXUR) is committed to the development of next-
generation standard ophthalmic therapies for the treatment of retinal diseases.
Oxurion's head office is in Leuven. Further information is available at
www.oxurion.com.
Important information on forward-looking statements
Certain statements contained in this press release may be considered as
"forward-looking". These forward-looking statements are based on current
expectations and are therefore subject to various risks and uncertainties. The
company therefore cannot guarantee that these forward-looking statements will
materialise and does not undertake to update or revise them, whether as a result
of new information, future events or for any other reason. Additional
information on the risks and uncertainties affecting the company and other
factors that could cause actual results to differ materially from forward-
looking statements is included in the company's annual report. This press
release does not constitute an offer or an invitation to sell or buy securities
or assets of Oxurion in any jurisdiction. No Oxurion securities may be offered
or sold in the United States without registration under the 1933 U.S. Securities
Act as amended, or pursuant to a waiver of such Act, and in accordance with all
applicable state securities laws.
For further information, please contact:
Oxurion NV
Pascal Ghoson, Chief Executive Officer
pascal.ghoson@oxurion.com (mailto:pascal.ghoson@oxurion.com)
Backstage Communication
Jurgen Vluijmans, Partner
jurgen@backstagecom.be (mailto:pascal.ghoson@oxurion.com)
Â